Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.

Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, Shivanna V, Indran SV, Zhang L, Smith JK, Perez D, Juelich TL, Morozov I, Wilson WC, Freiberg AN, Richt JA.

PLoS One. 2017 Dec 21;12(12):e0189250. doi: 10.1371/journal.pone.0189250. eCollection 2017.

2.

Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells.

Lokugamage N, Ikegami T.

NPJ Vaccines. 2017;2. pii: 20. doi: 10.1038/s41541-017-0021-9. Epub 2017 Jul 17.

3.

Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.

Ly HJ, Nishiyama S, Lokugamage N, Smith JK, Zhang L, Perez D, Juelich TL, Freiberg AN, Ikegami T.

Vaccine. 2017 Dec 4;35(48 Pt B):6634-6642. doi: 10.1016/j.vaccine.2017.10.036. Epub 2017 Oct 20.

4.

Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.

Ly HJ, Lokugamage N, Nishiyama S, Ikegami T.

PLoS One. 2017 Sep 19;12(9):e0185194. doi: 10.1371/journal.pone.0185194. eCollection 2017.

5.

Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Nishiyama S, Slack OA, Lokugamage N, Hill TE, Juelich TL, Zhang L, Smith JK, Perez D, Gong B, Freiberg AN, Ikegami T.

Virulence. 2016 Nov 16;7(8):871-881. Epub 2016 Jun 1.

6.

Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression.

Phoenix I, Lokugamage N, Nishiyama S, Ikegami T.

Viruses. 2016 May 24;8(6). pii: E151. doi: 10.3390/v8060151.

7.

N-Glycans on the Rift Valley Fever Virus Envelope Glycoproteins Gn and Gc Redundantly Support Viral Infection via DC-SIGN.

Phoenix I, Nishiyama S, Lokugamage N, Hill TE, Huante MB, Slack OA, Carpio VH, Freiberg AN, Ikegami T.

Viruses. 2016 May 23;8(5). pii: E149. doi: 10.3390/v8050149.

8.

Application of Droplet Digital PCR to Validate Rift Valley Fever Vaccines.

Ly HJ, Lokugamage N, Ikegami T.

Methods Mol Biol. 2016;1403:207-20. doi: 10.1007/978-1-4939-3387-7_10.

PMID:
27076132
9.

The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Nishiyama S, Lokugamage N, Ikegami T.

J Virol. 2016 Jan 27;90(7):3735-44. doi: 10.1128/JVI.02241-15.

10.

Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, Lokugamage N, Korman L, Morrill JC, Peters CJ.

Vaccine. 2016 Jan 20;34(4):523-530. doi: 10.1016/j.vaccine.2015.11.078. Epub 2015 Dec 17.

11.

Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL, Gong B, Slack OA, Ly HJ, Lokugamage N, Freiberg AN.

J Virol. 2015 Jul;89(14):7262-76. doi: 10.1128/JVI.00135-15. Epub 2015 May 6.

12.

Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Morrill JC, Laughlin RC, Lokugamage N, Wu J, Pugh R, Kanani P, Adams LG, Makino S, Peters CJ.

Vaccine. 2013 Oct 9;31(43):4988-94. doi: 10.1016/j.vaccine.2013.08.003. Epub 2013 Aug 27.

13.

Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus.

Lihoradova OA, Indran SV, Kalveram B, Lokugamage N, Head JA, Gong B, Tigabu B, Juelich TL, Freiberg AN, Ikegami T.

PLoS Negl Trop Dis. 2013 Apr 18;7(4):e2181. doi: 10.1371/journal.pntd.0002181. Print 2013.

14.

Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.

Indran SV, Lihoradova OA, Phoenix I, Lokugamage N, Kalveram B, Head JA, Tigabu B, Smith JK, Zhang L, Juelich TL, Gong B, Freiberg AN, Ikegami T.

J Gen Virol. 2013 Jul;94(Pt 7):1441-50. doi: 10.1099/vir.0.051250-0. Epub 2013 Mar 20.

15.

Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, Weise WJ, Adams LG, Makino S, Peters CJ.

Vaccine. 2013 Jan 7;31(3):559-65. doi: 10.1016/j.vaccine.2012.10.118. Epub 2012 Nov 12.

16.

Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR.

Kalveram B, Lihoradova O, Indran SV, Lokugamage N, Head JA, Ikegami T.

Virology. 2013 Jan 20;435(2):415-24. doi: 10.1016/j.virol.2012.09.031. Epub 2012 Oct 12.

17.

Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Lokugamage N, Freiberg AN, Morrill JC, Ikegami T.

J Virol. 2012 Dec;86(24):13566-75. doi: 10.1128/JVI.02081-12. Epub 2012 Oct 3.

18.

The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.

Lihoradova O, Kalveram B, Indran SV, Lokugamage N, Juelich TL, Hill TE, Tseng CT, Gong B, Fukushi S, Morikawa S, Freiberg AN, Ikegami T.

J Virol. 2012 Jul;86(14):7650-61. doi: 10.1128/JVI.00778-12. Epub 2012 May 9. Erratum in: J Virol. 2013 Nov;87(22):12507.

19.

Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA.

Morrill JC, Ikegami T, Yoshikawa-Iwata N, Lokugamage N, Won S, Terasaki K, Zamoto-Niikura A, Peters CJ, Makino S.

PLoS One. 2010 Apr 1;5(4):e9986. doi: 10.1371/journal.pone.0009986. Erratum in: PLoS One. 2010;5(4). doi: 10.1371/annotation/326c5f5b-3da9-4b0b-b889-28d4f33d2543.

20.

A comparative epidemiological study of hantavirus infection in Japan and Far East Russia.

Kariwa H, Lokugamage K, Lokugamage N, Miyamoto H, Yoshii K, Nakauchi M, Yoshimatsu K, Arikawa J, Ivanov LI, Iwasaki T, Takashima I.

Jpn J Vet Res. 2007 Feb;54(4):145-61. Review.

PMID:
17405352

Supplemental Content

Loading ...
Support Center